The way we test for Helicobacter pylori (H. pylori), a common bacteria that can cause stomach ulcers, is undergoing a transformation! The Helicobacter Pylori Non-Invasive Testing Market is poised for steady growth, reaching an estimated USD1 billion by 2033. This signifies a rise from a current market value of USD650.50 million in 2023, with a moderate Compound Annual Growth Rate (CAGR) of 4.4%. This surge in non-invasive testing reflects a growing preference for convenient and painless methods to diagnose H. pylori infections.
The increasing prevalence of Helicobacter pylori bacterial infection, increased governmental awareness about infection for accurate diagnosis, and the launch of new products and approval of those products by the Food and Drug Administration are expected to drive the growth of the Helicobacter pylori non-invasive testing market. Although there is potential for helicobacter pylori non-invasive testing demand, it is unlikely to materialize due to issues such as a low detection rate, the absence of any outward symptoms, and stringent regulatory constraints. Nonetheless, doctors have advised patients to seek treatment for H. Despite the lack of evidence linking COVID-19 and the virus, Pylori infections should be treated as soon as possible.
Request a Sample Copy of this Report!
https://www.futuremarketinsights.com/reports/sample/rep-gb-15823
North America has the largest market share for non-invasive Helicobacter pylori (H. pylori) testing, while Asia-Pacific has the fastest growth. The North American helicobacter pylori non-invasive testing market is expected to expand throughout the forecast period, owing to rising rates of gastric cancer, duodenal ulcers, and gastric ulcers, as well as improvements in healthcare infrastructure.
Throughout the forecast period, the market for non-invasive H. pylori is expected to spread fastest in Asia Pacific. China, India, and Japan are just a few of the countries in the region where non-invasive helicobacter pylori testing is expected to grow rapidly in the coming years. As Asia and the Pacific’s population ages, so does the prevalence of Helicobacter pylori (H. pylori) and gastric cancer cases, so does the market for non-invasive H. pylori testing. pylori is expected to spread. That is why there is so much room for growth in the region for helicobacter pylori non-invasive testing market players throughout the forecasted expansion period.
Helicobacter Pylori Non-Invasive Testing Market Key Takeaways
- The rise in non-invasive testing for Helicobacter pylori (H. pylori) is expected to drive demand for H. pylori non-invasive tests. pylori diagnosis and a scarcity of endoscopic resources
- The demand for non-invasive helicobacter pylori (H. pylori) testing is increasing due to increased government awareness of infection and the need for accurate diagnosis, rising demand for point-of-care testing equipment, and the widespread availability of diagnostic tests.
- The demand for helicobacter pylori (H. pylori) non-invasive testing is expected to rise as a result of factors such as the increasing prevalence of H. pylori. pylori infection, the introduction of new products, and the Food and Drug Administration’s approval of these products
- The global aging population and the rising number of people with stomach ulcers are expected to fuel the growth of the helicobacter pylori non-invasive testing market.
- The adoption of non-invasive testing for helicobacter pylori (H. pylori) is expected to grow during the projected period due to rising technical developments and an increase in innovations.
- The demand for non-invasive tests to identify Helicobacter pylori (H. pylori) is projected to face challenges such as a low detection rate, the fact that H. pylori infection often has no symptoms, and strict regulatory regulations.
Helicobacter Pylori Non-Invasive Testing Market Competitive Landscape
The global helicobacter pylori non-invasive testing market comprises of the following players: Meridian Bioscience, Inc., DiaSorin S.p.A, Alere, Sekiusi Diagnostics, and Biomerica, Inc. Besides these, a host of other players have a significant market presence as well. These are Biohit Oyj, Exalenz Bioscience Ltd., Aalto Bio Reagents Ltd., Certest Biotec S.L. and CorisBioconcept SPRL.
Helicobacter Pylori Non-Invasive Testing Market Recent Developments
Meridian Bioscience, Inc. has received FDA approval to market its novel Curian and Curian HpSA assays in March 2020. The new analyzer and preliminary assay are critical components of their strategy to maintain market dominance in gastrointestinal disease testing.
Thermo Fischer Scientific, a world-renowned provider of clinical research services to the biopharma and biotech industries, announced in December 2021 that it is expected to acquire PPD, Inc. for US$17.4 billion.
Key Segments in the Helicobacter Pylori Non-Invasive Testing Market
By Non-invasive Test Type:
- Serology Test
- Stool Antigen Test
- Urea Breath Test
By Test Type:
- Laboratory-based Tests
- Point-of-Care Tests
By End-user:
- Hospitals
- Diagnostic Labs
- Clinics
Buy Report Now!
https://www.futuremarketinsights.com/checkout/15823
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube